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ABSTRACT
Objectives: Of estimated 112 million persons infected with
chronic hepatitis B (CHB) in China, 15% to 40% will even-
tually develop liver complications. Most patients do not
actively seek antiviral agents for treatment due in part to lack
of good understanding of the disease. Entecavir is a new
therapeutic option for CHB patients and the purpose of this
study was to evaluate the cost-effectiveness of entecavir treat-
ment in China, based on projected clinical beneﬁts from its
superior viral suppression efﬁcacy.
Methods: The analysis was based on the perspective of the
Chinese Social Security program. Adjusted relative risks on
the association between viral load (VL) and clinical end
points (liver cirrhosis/hepatocellular carcinoma) were derived
from a publication of a Taiwan CHB prospective cohort with
42,115 person-years of follow-up, and applied to patients
enrolled in a randomized phase III trial in China. In this trial,
hepatitis B virus (HBV) DNA (by polymerase chain reaction
assay) was the key efﬁcacy end point after 48 weeks of treat-
ment with either entecavir or lamivudine monotherapy.
Entecavir and lamivudine daily prices were assumed to be
Renminbi Yuan (RMB) 40 and 16.71, respectively. Life
expectancy tables were based on China vital statistics. Direct
medical cost and utility scores for different phases of CHB
were estimated from published China speciﬁc data, and costs
were adjusted to 2006 values using the Chinese Consumer
Price Index. Probabilistic sensitivity analyses were conducted
to evaluate parameter uncertainty on event distribution and
treatment failure rates beyond the trial period.
Results: A total of 519 subjects were enrolled in the study,
comprising of 82% males, 87% HBeAg+, and a mean age of
30 years. Based on the efﬁcacy measurement of the percent-
age of patients achieving HBV DNA <300 copies/ml at week
48, entecavir was superior to lamivudine (78.7% vs. 46.7%,
respectively [P < 0.05]). In the base case, compared with
lamivudine, 1 year of entecavir therapy gained 0.305 quality-
adjusted life year (QALY) at an incremental cost of 5368
RMB, with a 3% annual discount. Compared with lamivu-
dine, using entecavir cost an incremental 17,590 RMB per
QALY gained (95% CI 6333–56,407).
Conclusions: Based on the results of this study, entecavir is
likely to be cost-effective in treating hepatitis B patients in
China based on the World Health Organization’s recom-
mended maximum willingness to pay threshold.
Keywords: CHB, China, cost-effectiveness, entecavir, HBV
DNA, viral load.
Introduction
Chronic hepatitis B virus (HBV) infection is a progres-
sive liver disease which affects about 350 million
people worldwide. Chinese national surveys of the epi-
demiology of chronic hepatitis B (CHB) indicate that
approximately 112 million Chinese citizens are chroni-
cally infected with HBV, representing 32% of the
global disease burden. China is the country with the
single largest number of CHB affected persons [1].
HBV infection imposes a massive socioeconomic
burden in China because 30% of chronically infected
individuals subsequently develop progressive and
potentially fatal liver disease, and an estimated 20% of
these patients die of the complications of CHB infec-
tion [2]. It is estimated the annual medical cost for a
patient with CHB or compensated cirrhosis (CC) is
around 10% of the average Beijing resident’s annual
income. Moreover, the annual medical cost for a
patient with decompensate cirrhosis (DC) or hepato-
cellular carcinoma (HCC) far exceeds their annual
income [3].
Unfortunately, only a small minority of patients
who might beneﬁt from the antiviral therapy have
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received treatments. The potential reasons for this
include (but are not limited to) an evolving under-
standing of different treatment approaches, side effects
of therapies such as inteferons, relatively high rate of
emergent drug resistance with older oral antivirals
such as lamivudine (LVD), uncertainty of therapy’s
long-term clinical and economic outcomes, and high
treatment costs over a short period of time.
Currently, the most prescribed antiviral agent for
chronic HBV infection in China is LVD, which dem-
onstrates anti-HBV efﬁcacy and provides clinical
beneﬁts. Nevertheless, the occurrence of drug resistant
HBV mutations has generated concern among physi-
cians prescribing LVD [4–7]. A new deoxyguanine
nucleoside analog, named entecavir (ETV), has dem-
onstrated excellent suppression of HBV replication
without signiﬁcant side effects or evidence of mito-
chondrial toxicity. In addition, long-term clinical trial
data have not shown evidence of viral resistance [8].
This study aims to evaluate the cost-effectiveness of
ETV treatment compared to LVD, by translating the
HBV DNA reduction observed with ETV treatment in
a China phase III trial into estimates of gains in life
expectancy (LE) and medical cost offsets, to arrive at
an estimate of the incremental cost per qualify-
adjusted life year (QALY) saved. Use of such results
would be helpful to facilitate decision-making of for-
mulary listing of the government health insurance
program, and to provide perspective to physicians and
patients on new intervention that may offer both short
and long-term clinical and economic beneﬁts.
Methods
Theoretical Basis for Economic Modeling
Because CHB-related liver complications usually take
years to become apparent, a typical clinical trial with
1-year follow-up is not adequate for capturing the
treatment impact on the clinical events. Thus, it is
often necessary to use surrogate end points as substi-
tutes for projecting disease progression. The main sur-
rogate end points traditionally used to assess treatment
response include undetectable serum HBV DNA level,
HBeAg status, normalization of alanine aminotrans-
ferase (ALT) level, and improvement in liver histology.
Nevertheless, a growing body of evidence suggests that
both ALT level and HBeAg seroconversion are poor
predictors of long-term disease outcome and their
associations with a reduction of risk of cirrhosis and
HCC is still under debate [3,9]. Evidence suggests that
HBV DNA is a more appropriate prognostic marker of
liver disease progression [9–11]. Therefore, therapies
which impact this marker may provide a useful index
of the effectiveness of treatments.
The study data on risk of disease progression based
on the level of viral load were derived from the Risk
Evaluation of Viral Load Elevation and Associated
Liver Disease/Cancer-Hepatitis B Virus (REVEAL-
HBV) study [10,11]. This was a prospective cohort
study which showed that, hepatitis B viral load was a
strong independent predictor of liver cirrhosis and
HCC events (Table 2) [11–13].
Description of Economic Model Structure
Following the clinical trial design, a previously pub-
lished decision tree model was used to evaluate the
cost-effectiveness of ETV compared to lamuvidine in
suppressing HBV DNA to an undetectable level [14].
An illustrative conceptual model framework is shown
in Figure 1. In brief, a hypothetical cohort of 1000
CHB patients either received LVD or ETV at the model
entry; these patients might develop viral resistance
with continued drug use or experience viral rebound
after the treatment cessation. HBV DNA values were
updated annually to incorporate the ﬁrst year trial
efﬁcacy results and the impacts from subsequent devel-
opment of viral resistance or viral rebound after
treatment cessation. CC, DC, and HCC events were
projected within 10 years, separately, at a population
level, using the published REVEAL-HBV risk predict-
ing models. The annual incidence rates for subjects
with hepatitis B viral load <300 copies/ml were 0.34%
for CC, 0.02% for DC, and 0.11% for HCC [10,11].
The study perspective was from that of a China
social security program responsible for all direct
health-care expenditures. Costs and life years were
discounted at an annual rate of 3%. All model param-
eters and data input values are provided in Table 2.
Statistical software (SAS, SAS Institute, Cary, NC,
USA) was used for all data analyses, and a spreadsheet-
based model using Visual Basic for Applications
(Microsoft Corporation, Redmond, WA, USA) was
created for all modeling and simulation executions.
Clinical Efﬁcacy Data
Efﬁcacy and safety. Efﬁcacy and safety data came
from BMS-AI463023 [15], a randomized (1:1),
double-blind, double-dummy phase III study enrolled
exclusively in China, comparing the safety and efﬁcacy
of ETV 0.5 mg once daily (QD) to LVD 100 mg QD
administered for 1 year to subjects with chronic HBV
infection. Randomization was stratiﬁed by hepatitis B
e antigen (HBeAg) status and investigative site. The
primary objective was to determine the proportion of
subjects treated with ETV who achieved a response for
the composite end point (week 48 virological and bio-
chemical response), which included our end point of
interest—week 48 serum HBV DNA by polymerase
chain reaction (PCR) assay.
After 1 year of treatment, ETV resulted in superior
clinical beneﬁt over LVD in treating nucleoside-naïve
patients with chronic HBV infection, measured by
reduction in HBV DNA and normalization of ALT.
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ETV was well tolerated, with a safety proﬁle compa-
rable to that of LVD. Because of the equivalent safety
results between therapies, the risk and costs of drug-
related adverse events were not considered in the
analysis.
Study patient and time. An intent-to-treat analysis
was conducted. Patients with missing HBV DNA data
at either baseline or week 48 were treated as missing
and excluded in the primary analyses. An alternative
imputation method using Last Observation Carried
Forward was also implemented, but had minimal
impact on our ﬁndings. The study period was from a
patient’s randomization to the end of blinded treat-
ment or week 48, whichever came ﬁrst.
Cost Estimates
Two cost components were considered in the analyses:
study drug costs and medical costs of treating liver
complications. Indirect medical costs and lost pro-
ductivity were not included in the analyses. Costs
are expressed in year 2006 Renminbi Yuan (RMB)
(US $ 1 = 7.55 RMB, as of September 12, 2007).
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Figure 1 Illustrative model diagram of 10-year disease progression.This is a modiﬁed tree model projecting disease risks based on current HBV DNA
levels. CC, compensated cirrhosis; CHB, chronic hepatitis B; DC, decompensate cirrhosis; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.
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All drug costs were calculated based on the actual
usage of study drugs (97% compliance) recorded on
the clinical trial Case Report Forms. The daily acqui-
sition cost of ETV 0.5 mg was 40 RMB, and 16.71
RMB for LVD 100 mg and 21 RMB for adefovir as
a salvage therapy, based on current ofﬁcial prices
approved by Shanghai municipal bureau of pricing.
The annual costs of study drugs were estimated by the
daily costs multiplied by number of days of drug use in
the trial.
Annual medical costs including inpatient, outpa-
tient, and laboratory tests were derived from the pub-
lished Chinese cost data: 1500 RMB for CC, 13,803
RMB for DC, and 38,450 RMB for HCC [3]. These
costs were then adjusted using the Consumer Price
Index in China [16], and applied to patients at the time
when events occurred and until they died. The actual
clinical trial outpatient physician visits and those of
laboratory tests recorded in the trial were excluded
from the cost estimates because there were largely
driven by the study protocol and therefore were nearly
identical in both treatment arms.
Life Year Gain and Utility Estimates
Age- and gender-speciﬁc LE estimate for CHB and CC
were based on the published vital data for the general
population [17]. LE for DC or HCC was estimated
based on the declining exponential approximation of
LE method: inverse of annual event mortality [18].
Annual mortality was assumed to be 23.3% for HCC
and 14.4% for DC [19,20].
All CHB patients were assigned a baseline utility of
0.71 at entry—meaning that 1 year of life in a person
with CHB would be equivalent to 0.71 year of healthy
life, and an estimated utility weight of 0.76 for CC,
and 0.266 for DC, and 0.30 for HCC. Ratings of
CHB-associated health states were elicited from a rep-
resentative sample of 100 uninfected individuals in the
China using a visual analog scale and weighted using
the standard gamble method [21].
Other Modeling Assumptions
To appropriately discount the subsequent medical
costs and life year lost after these events had occurred,
in the base case analysis, we deterministically assigned
average time to events, about 8 years based on the
observed event time in the REVEAL-HBV cohort, to
the trial patients who later developed a CC, DC or
HCC event, although we also modeled time to event
probabilistically later in the sensitivity analyses.
In the reference case analysis, the distributions of
subjects with different HBV DNA levels beyond the
ﬁrst year after the ETV or LVD treatment cessation
were assumed based on a published study range
showing the cumulative reappearance rates for serum
HBV-DNA following cessation of LVD therapy at
1 year was 48% [22]. For those responders who failed
to reach the undetectable viral level in the next year,
they would be evenly allocated into four higher HBV
DNA categories. The number of events were ﬁrst pro-
jected based on the ﬁrst-year observed HBV DNA
data, and then repeated for each year based on viral
rebound-adjusted viral data from years 2 to 10, and an
average of these projections were used for our ﬁnal
estimate of number of liver cirrhosis and HCC events.
Sensitivity Analyses
To investigate whether our ﬁndings are robust and
sensitive to any input parameter variation, we ﬁrst ran
the univariate sensitivity analyses on the following
input variables based on their possible ranges
(Table 2): age, gender, drug price, treatment duration,
viral resistance rate for ETV after 2 years, event
medical costs, and time to event. We also ran alterna-
tive sensitivity analyses on the following key input
parameters:
First, utility scores have rarely been measured for
CHB patients, the utilities for liver complications used
in this study relied on a single survey study for CHB
patients. To test the impact of varying utility scores
for the liver complications on our cost-effectiveness
results, a different set of published utility tariff values
was also used [23], but were not chosen for the base
case analyses as their utility scores were primarily
derived from the surveys on hepatitis C patients.
To evaluate whether ETV for a longer term use is
also cost-effective, we extended duration of ETV treat-
ment for 3, 5, and 10 years, assuming the trial efﬁcacy
observed for ETV in the ﬁrst year would sustain
beyond the trial period. Because the viral resistance
problem has been well documented for patients taking
LVD, we assumed that, as long as the patients were
taking LVD, there were additional patients who would
develop treatment resistance each year, the cumulative
LVD viral resistance rate from years 1 to 5 were: 14%,
38%, 49%, 66%, 69% [24], and stayed 69% beyond
5 years. Once they developed LVD resistance, they had
to switch to use adefovir as a salvage therapy, although
assuming that their viral load would not worsen. In a
separate sensitivity analysis, we also assumed that
patients developing LVD resistance would be treated
with the addition of adefovir to LVD therapy to reﬂect
recent clinical practice in the management of
lamvudine-resistance patients although conservatively
assuming the treatment efﬁcacy would be maintained.
We assumed no treatment resistance for ETV therapy
based on the recent long-term trial data [7].
To evaluate uncertainty with respect to model
parameters, probabilistic sensitivity analyses with
1000 iterations were conducted for the following two
key parameters with the biggest uncertainty concern:
1) viral rebound rates after the treatment cessation:
a beta distribution with values for shape parameters
alpha (38.88) and beta (42.12) derived from the
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reported mean and standard deviation of viral rebound
rates; and 2) time to the ﬁrst event: a gamma distribu-
tion with the sample mean (survival years, CC 7.6; DC
8.6; HCC 7.1) and standard deviation (CC 3.95; DC
2.77; HCC 3.53) observed from the REVEAL-HBV
cohort. A gamma distribution was deemed appropriate
because time to event was constrained to be positive
and the gamma distribution is only deﬁned for positive
values.
Incremental Cost-Effectiveness Ratio (ICER) Benchmark
in China
Certainly, the lower the cost-effectiveness ratio, the
better, but what should determine an upper limit? In
the United States, $100,000 to $150,000 per QALY
has become an accepted benchmark for policymakers
and insurance agencies [25]. But that level is unlikely
to be sustainable in developing countries like China.
The World Health Organization’s Commission on
Macroeconomics and Health [26] recommended
choosing interventions that had cost-effectiveness
ratios less than three times the Gross National Income
(GNI) per capita. With a GNI per capita of $2228.9 in
China in 2005, based on the ofﬁcial report from the
World Bank, assuming a 10% growth rate in 2006, we
estimated that 55,533 RMB could be an acceptable
maximum willingness to pay threshold. To put the
estimated cost-effectiveness ratios in context from a
Chinese social security program perspective, we used
this benchmark to determine whether ETV treatment
would ﬁt within their maximum willingness to pay for
the values.
Results
Demographic characteristics were balanced between
treatment groups (Table 1). The majority of treated
subjects were male (82%) and Asian (100% Chinese),
with a mean age of 30 years. HBV disease character-
istics were comparable between the two treatment
groups. All subjects had detectable HBsAg at baseline.
Most subjects were HBeAg-positive at baseline
(ETV 87%, LVD 85%). The mean baseline ALT was
comparable for the two treatment groups (ETV
195.55 U/L, LVD 197.56 U/L).
Mean baseline HBV DNA levels were comparable
for the 2 treatment groups using the bDNA assay
(ETV 2.56 log10 MEq/ml, LVD 2.42 log10 MEq/ml) and
PCR assays (ETV 8.64 log10 copies/ml, LVD 8.48 log10
copies/ml).
The estimated clinical and economic outcomes are
reported in Table 2 and Table 3. ETV was superior to
LVD for the proportion of subjects who achieved HBV
DNA <300 copies/ml by PCR assay at week 48. At the
end of 48-week trial period, there were 79% patients
in the ETV arm, and 47% patients in LVD arm, reach-
ing the predeﬁned undetectable HBV DNA goal, <300
copies/ml, costing 16,807 RMB per patient to reach
this goal.
Among a hypothetical cohort of 1000 patients, we
projected that there would be 32, 5, and 19 fewer cases
of CC, DC, and HCC events, respectively, in the ETV
arm, compared to the LVD arm. These translated into
about 2.9 million RMB medical cost offsets, and gain
an aggregate 385 life years in 10 years, with ETV
treatment.
With a daily drug cost of 40 RMB for ETV, 1 year
of ETV therapy gained 0.305 QALY at an incremental
cost of 5368 RMB, with a 3% annual discount.
Compared with LVD, using ETV cost an incremental
17,590 RMB per QALY gained (95% CI 6333–
56,407).
Univariate sensitivity analyses showed that our
ﬁndings are most sensitive to drug prices, treatment
duration, efﬁcacy, discount rate, age, and cost, but not
sensitive to gender. ICER, estimated using alternative
utility scores [23]: 0.99 for CHB, 0.80 for CC, 0.60 for
DC, and 0.73 for (HCC), was 13,330 RMB, a more
favorable result. Although LVD does not have a
generic version available yet in China, to evaluate the
possible impact of generic LVD on our research results,
we assumed 20% discount for general LVD price
(based on the current adefovir prices in China as a
analog: brand 25 RMB, generic 21 RMB), this yielded
an ICER estimate of 21,452 RMB, still well below
55,533 RMB threshold.
A plot of the probabilistic sensitivity analysis
(PSA)—derived joint distribution of cost and effective-
ness is shown in Figure 2, most points lie below the
cost-effectiveness threshold, indicating that there is
high possibility that the ETV therapy is cost-effective.
Cost-effectiveness acceptability curves are shown in
Figure 3. The favorable cost-effective results are very
Table 1 Baseline demographics and HBV characteristics
(BMS-AI463023)
Characteristic
ETV 0.5 mg
(n = 258)
LVD 100 mg
(n = 261)
Age, years
Mean (SE) 30 (0.5) 30 (0.6)
Gender, n (%)
Male 211 (82) 217 (83)
Female 47 (18) 44 (17)
Race, n (%)
Asian/Paciﬁc Islanders 258 (100) 261 (100)
HBV DNA by PCR, log10 copies/ml
Mean (SE) 8.64 (0.062) 8.48 (0.069)
HBV surface antigen: n (%)
Postive 258 (100) 261 (100)
HBV E antigen: n (%)
Postive 220 (87) 212 (85)
Negative 38 (13) 49 (15)
ALT, U/L
Mean (SE) 195.55 (8.716) 197.56 (11.15)
ALT, alanine aminotransferase; ETV, entecavir; HBV, hepatitis B virus; LVD, lamivudine;
PCR, polymerase chain reaction.
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robust, with 97.6% of PSA-derived ICER estimates
below a hypothetic 55,533 RMB/QALY threshold.
Longer term modeling also showed that 3, 5, or
10 years of ETV treatment would still be cost-effective,
yielding an incremental cost per QALY saved of
44,511, 54,358, and 67,874, in RMB, respectively
(Fig. 3), assuming that LVD-resistant patients would
switch to adefovir monotherapy. Alternatively, in
a separate sensitivity analysis assuming that the
treatment-resistant patients would use add-on ade-
fovir, ICERs were lower, ranging from 37,496 (3 years)
to 36,447 (10 years), primarily due to the relatively
higher cost of adefovir adding-on therapy.
Discussion
The major health risks and economic impacts associ-
ated with CHB infection seem to be primarily driven
by the later development of HCC and complications of
DC. In China, CHB infection is an important cause of
HCC, particularly among individuals during the most
productive decades of life span. Current management
options for HCC remain limited partly because there is
a paucity of sensitive methods for early diagnosis,
resulting in most patients late in the disease course.
Liver transplantation remains the only effective
therapy for late complications like DC and HCC;
unfortunately, this treatment is relatively too expensive
and unavailable to the overwhelming majority of
patients in China.
Although availability of HBV vaccine world wide
including China, the high prevalence of HBV remains
one of the signiﬁcant public health issues in China due
to its burden to the society. One major reason is that
there is an enormous human reservoir for the virus
given the very high rate of maternal-neonatal and hori-
zontal transmission among children, and this is com-
pounded by the fact that most infections early in life
are asymptomatic; thus, most cases are not detected
clinically. Therefore, the beneﬁts of early treatment for
CHB in suppressing the viral and reducing consequent
risk of cirrhosis and HCC are substantive. The added
demonstration of cost-effectiveness of such treatment
from a China social security program perspective
would inform decision-making in the light of limited
health-care resources in the country.
The disease progression data used in this model
were derived from the recently published REVEAL-
HBV study [10,11] which showed that the incidence
rates of HCC and cirrhosis increased across a biologi-
cal gradient of serum HBV DNA levels in a dose–
response relationship. These ﬁndings implicate viral
replication in the progression of chronic HBV infection
and contribute to the rationale for antiviral therapy to
arrest progression of liver disease [27]. Although the
REVEAL-HBV study provides the most robust infor-
mation on the relationships between viral load and
disease progression and mortality, it is not the only
source of evidence to show this. In another prospective
cohort study [28] conducted in Haimen city, China,
with 11 years of follow-up, it was shown that cohort
entry HBV viral load was a signiﬁcant predictor of
mortality and morbidity from HCC and chronic liver
disease. Several studies have demonstrated similar
ﬁndings [29–31]. Additionally, in studies of patients
with HCC who have undergone surgery, one of the
strongest predictors of tumor recurrence is the amount
of circulating virus as measured by the HBV DNA
[32,33].
In this model, we have assumed that risk of hepatic
complications seen in patients with low viral loads can
be simulated by reducing the viral load with antiviral
therapy. Whereas the magnitude of the risk reduction
may vary and is currently not known, the principle of
this assumption is not only logical but biologically
plausible. In a large meta-analyses of 26 prospective
mostly registration studies with a total of 3428 study
subjects (2524 were HBeAg-positive at baseline), the
level of viral replication and the change in viral repli-
cation were signiﬁcantly correlated with histological
grading and change in histological grading, serological
and biochemical response [34]. An Italian study pub-
Table 3 Cost-effectiveness results for entecavir versus lamivudine
Entecavir 0.5 mg Lamivudine 100 mg Difference
Number of CHB patients at entry 1,000 1,000
Duration of treatment (years) 1 1
Total discounted drug costs 14,159,167 5,893,269 8,265,898
Projected liver complication in 10 years
Compensated cirrhosis 115 147 32
Decompensate cirrhosis 10 15 5
HCC 56 76 19
Total discounted medical costs 8,646,279 11,544,164 -2,897,884
Discounted life year lost 1,075 1,460 385
Discounted QALY lost 853 1,158 305
Cost per life year saved 13,958
Cost per QALY saved 17,590
All costs are expressed in 2006 RMB.
CHB, chronic hepatitis B; HCC, hepatocellular carcinoma; QALY, quality-adjusted life year.
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lished in 2004 showed that in about 656 HBeAg-
negative CHB subjects treated with LVD, the presence
of resistance as determined by viral breakthrough and
rebound had a worse outcome in all parameters
including mortality when compared to those that
were effectively suppressed by LVD. This study was
in patients with eAntigen-negative disease where
immune-induced seroconversion is not an option and
therefore the beneﬁt of therapy is from direct antiviral
effect of the drug [35]. Indeed, decrease in viral load
through antiviral therapy has been associated with
histological improvement [36–42], increased survival
of patients with decompensate liver disease from hepa-
titis B [43–51], and improved clinical outcome in
patients with HBV reactivation following chemo-
therapy [29,31,52–62]. Finally, a blinded placebo con-
trolled randomized clinical trial has demonstrated that
in CHB patients with advanced ﬁbrosis, effective sup-
pression of viral replication with an antiviral drug
resulted in dramatic reductions in progression to more
severe liver disease. This study proves the principle
that informed the current model by demonstrating
that the level of suppression achieved by an antiviral
drug has a causal relationship with the risk of disease
progression [63].
Although clinical beneﬁts of reducing viral load
have been demonstrated in recent literature, to the best
of our knowledge only one other economic analyses
has been conducted based on the end point of antiviral
therapy-induced suppression of viral replication [64].
In that analysis, data from the REVEAL-HBV study
was used to inform the disease state progression prob-
abilities and the economic value of effectively suppress-
ing viral replication in immune tolerant patients (who
currently do not qualify for therapy under current
guidelines) was shown in that analysis. Ours is there-
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fore the ﬁrst analyses applying this end point in a
population of patients that meet all current treatment
guidelines for therapy.
HBeAg seroconversion has traditionally been
thought of as uniformly good outcome for patients,
and for some it still is, but recent data have shown that
many patients who have undergone HBeAg serocon-
version still go on to develop severe complications
(including HCC) [65]. Seroconversion and the absence
of HBeAg are probably still important clinical end
points, but the risk of disease progression even with
these end points being met still depends on the degree
of ongoing viral replication in the host. The ultimate
goal of therapy for patients with chronic HBV infec-
tion is to prevent progression of liver disease to cirrho-
sis and HCC. Because HBV replication is implicated in
the outcome of chronic HBV infection, the primary
aim of therapy is durable suppression of serum HBV
DNA to the lowest levels possible. This, in turn, will
lead to the other aims of therapy, including histological
improvement and ALT normalization [27]. Histori-
cally, the presence (i.e., levels greater than assay limit
of detection) or absence (i.e., levels less than assay
limit) of HBV DNA by hybridization techniques was a
major determinant of treatment candidacy. Undetect-
able HBV DNA levels by hybridization techniques
have in the past been considered clinically insigniﬁ-
cant. With the advent of sensitive real-time PCR,
serum HBV DNA has become the most useful mea-
surement, and enables the accurate monitoring of HBV
DNA at levels as low as 10 IU/ml, which has been
recommended to be used to establish a patient’s base-
line HBV DNA level before treatment and to monitor
response to antiviral therapy or viral rebound associ-
ated with resistance [27].
Our analyses are conservative in many aspects
which have been described in details elsewhere [14]. In
addition, we did not include indirect medical costs,
caregiver support cost, and lost productivity in this
study because national representative data of indirect
costs are not reported in China; however, we believe
that these indirect disease burdens could be very sig-
niﬁcant and costly to the China society and individual
Chinese patients. Inclusion of such indirect costs
would make the cost-effectiveness of ETV even more
favorable.
Our study results still need to be viewed with
caution. The longer-term treatment rebound rates for
both drugs are so far not available. The optimal dura-
tion of ETV or LVD administration in CHB patients
remains to be determined due to frequent relapse after
cessation the therapy. Further studies are also needed
to conﬁrm these modeling results and determine
whether a reduction in liver cirrhosis and HCC with
ETV therapy actually occurs. Probabilistic sensitivity
analysis needs to consider more model parameter
uncertainty.
The potential cost-effectiveness for ETV compared
with other drugs such as adefovir or interferon was not
evaluated due to lack of head-to-head randomized trial
data. Nevertheless, some recent published studies have
shown that ETV is even more superior to adefvior in
suppressing viral load [66–68].
Although we accounted for the actual compliance
rate in the trial, we would expect the compliance rate
in the real world practice would be much lower.
Nevertheless, we still yet need to determine the poten-
tial impact of compliance on treatment efﬁcacy.
In conclusion, our model consistently showed that
both the short-term and long-term use of ETV is likely
to be not only clinically effective but also economically
attractive for the China Social Security program.
Although eradication of hepatitis B is rarely achieved
with the current treatments, the availability of ETV as
part of an early treatment strategy for the current CHB
patients may be perceived as economically justiﬁable
to the China Social Security program. The treatment
target can be applied for both HBeAg-positive and
-negative patients and should result in prolonged viral
suppression of HBV DNA to levels at which liver
disease progression is unlikely to develop. Highly sen-
sitive testing methods based on polymerase chain reac-
tion (PCR) have become available for measuring serum
level of HBV DNA. A new guideline recommending a
simple treatment goal of achieving the undetectable
viral load goal level such as <300 copies/ML would be
more beneﬁcial to both physicians and patients when
rendering treatment decision.
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